In line with these results, we revealed that the proteasome inhibitor MG132 efficiently restored Cdk2 expression in SLCO4A1-AS1-depleted CRC cells, whereas the lysosome inhibitor NH4Cl was unable to block SLCO4A1-AS1 knockdown-induced degradation of Cdk2 (Fig. 5d). Here, CDK2 is linked to colorectal carcinoma.